Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Robust finite time cooperative control of second order agents:A Multi-input Multi-output higher order super-twisting based approach.

Kamal S, Sachan A, Kumar DK, Singh D.

ISA Trans. 2018 Nov 2. pii: S0019-0578(18)30420-8. doi: 10.1016/j.isatra.2018.10.041. [Epub ahead of print]

PMID:
30420136
2.

Molecular mapping of aluminium resistance loci based on root re-growth and Al-induced fluorescent signals (callose accumulation) in lentil (Lens culinaris Medikus).

Singh CK, Singh D, Tomar RSS, Karwa S, Upadhyaya KC, Pal M.

Mol Biol Rep. 2018 Sep 14. doi: 10.1007/s11033-018-4368-4. [Epub ahead of print]

PMID:
30218353
3.

Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.

Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D.

Pulm Pharmacol Ther. 2018 Feb;48:71-79. doi: 10.1016/j.pupt.2017.10.003. Epub 2017 Oct 4.

4.

Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease.

Singh D.

Tuberc Respir Dis (Seoul). 2017 Oct;80(4):317-324. doi: 10.4046/trd.2017.0080. Epub 2017 Sep 1. Review.

5.

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.

Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.

Respir Res. 2017 May 30;18(1):106. doi: 10.1186/s12931-017-0583-0.

6.

Erratum to: Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.

Singh D, Miravitlles M, Vogelmeier C.

Adv Ther. 2017 Mar;34(3):771. doi: 10.1007/s12325-017-0481-3. No abstract available.

7.

Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.

Singh D, Ciurlia G, Piccinno A, Muraro A, Bocchi M, Scuri M.

Pulm Pharmacol Ther. 2017 Feb;42:43-51. doi: 10.1016/j.pupt.2016.12.004. Epub 2017 Jan 5.

8.

Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management.

Singh D, Miravitlles M, Vogelmeier C.

Adv Ther. 2017 Feb;34(2):281-299. doi: 10.1007/s12325-016-0459-6. Epub 2016 Dec 15. Review. Erratum in: Adv Ther. 2017 Mar;34(3):771.

9.

Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design.

Singh D.

Handb Exp Pharmacol. 2017;237:243-264. doi: 10.1007/164_2016_70. Review.

PMID:
27838852
10.

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J.

Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.

PMID:
27598678
11.

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.

Singh D, Leaker B, Boyce M, Nandeuil MA, Collarini S, Mariotti F, Santoro D, Barnes PJ.

Pulm Pharmacol Ther. 2016 Oct;40:1-6. doi: 10.1016/j.pupt.2016.06.011. Epub 2016 Jun 29.

12.

Left unilateral electroconvulsive therapy in the presence of intracranial stainless steel wire.

Singh D, Peavey C, Bhatnager M, Hauptman J.

Aust N Z J Psychiatry. 2016 Dec;50(12):1210-1211. Epub 2016 Jun 23. No abstract available.

PMID:
27340109
13.

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.

Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.

Respir Res. 2016 Jun 18;17(1):73. doi: 10.1186/s12931-016-0387-7.

14.

Optimization of nonribosomal peptides production by a psychrotrophic fungus: Trichoderma velutinum ACR-P1.

Sharma R, Singh VP, Singh D, Yusuf F, Kumar A, Vishwakarma RA, Chaubey A.

Appl Microbiol Biotechnol. 2016 Nov;100(21):9091-9102. Epub 2016 Jun 10.

PMID:
27287849
15.

The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).

Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z; TRIDENT study investigators.

Respir Med. 2016 May;114:84-90. doi: 10.1016/j.rmed.2016.03.018. Epub 2016 Mar 26.

16.

Implantable Cardioverter-Defibrillator Discharge in a Patient with Dilated Cardiomyopathy: What Is the Mechanism?

Docekal J, Singh DK.

Card Electrophysiol Clin. 2016 Mar;8(1):173-6. doi: 10.1016/j.ccep.2015.10.023. Review.

PMID:
26920189
17.

Implantable Cardioverter-Defibrillator Shock Caused by Uncommon Variety of Nonreentrant Atrioventricular Nodal Tachycardia.

Singh DK, Badhwar N.

Card Electrophysiol Clin. 2016 Mar;8(1):57-60. doi: 10.1016/j.ccep.2015.10.004. Epub 2016 Jan 8. Review.

PMID:
26920170
18.

Use of the Surface Electrocardiogram to Define the Nature of Challenging Arrhythmias.

Singh DK, Peter CT.

Card Electrophysiol Clin. 2016 Mar;8(1):1-24. doi: 10.1016/j.ccep.2015.10.021. Review.

PMID:
26920165
19.

Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.

Donohue JF, Singh D, Munzu C, Kilbride S, Church A.

Respir Med. 2016 Mar;112:65-74. doi: 10.1016/j.rmed.2016.01.001. Epub 2016 Jan 7.

20.

Porcine acellular dermal matrix (PADM) vascularises after exposure in open necrotic wounds seen after complex hernia repair.

Gowda AU, Chang SM, Chopra K, Matthews JA, Sabino J, Stromberg JA, Zahiri HR, Pinczewski J, Holton LH 3rd, Silverman RP, Singh DP.

Int Wound J. 2016 Oct;13(5):972-6. doi: 10.1111/iwj.12558. Epub 2015 Dec 21. Review.

PMID:
26688300

Supplemental Content

Loading ...
Support Center